Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel–Lindau protein
The DOI matches its Crossref record; 20 of the 21 references it cites were found in a registry or an index.
Abstract
von Hippel-Lindau (VHL) disease is a hereditary cancer syndrome that is characterized by the development of multiple vascular tumors and is caused by inactivation of the von Hippel-Lindau protein (pVHL). Here we show that pVHL, through its beta-domain, binds directly to hypoxia-inducible factor (HIF), thereby targeting HIF for ubiquitination in an alpha-domain-dependent manner. This is the first function to be ascribed to the pVHL beta-domain. Furthermore, we provide the first direct evidence that pVHL has a function analogous to that of an F-box protein, namely, to recruit substrates to a ubiquitination machine. These results strengthen the link between overaccumulation of HIF and development of VHL disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the presence of oxygen (typically > 5% O2), the HIF-α subunit is hydroxylated by PHDs in an iron and oxygen dependent manner, which leads to HIF-α polyubiquitination by pVHL, targeting HIF-α for proteasomal degradation (Figure 2) [8].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [8]
In the citing paper
“As described in the AdPROM section, VHL acts as the substrate receptor for the Cul2-Rbx1 E3 ligase complex, recruiting HIF1α for its ubiquitination and degradation [88].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [88]
Citations
Cites
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Huang, L. E., Gu, J., Schau, M., & Bunn, H. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.7987 · Cited by 2,113
Mitochondrial reactive oxygen species trigger hypoxia-induced transcription
Chandel, N. S., Maltepe, E., Goldwasser, E., Mathieu, C. E., Simon, M. C., & Schumacker, P. T. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.20.11715 · Cited by 1,926 · cited 1×
“Whether hypoxia and desferroxamine utilize the same molecular mechanism(s) to stabilize HIF in vivo remains to be determine”
BackgroundSalceda, S., & Caro, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.36.22642 · Cited by 1,674
Structure of the VHL-ElonginC-ElonginB Complex: Implications for VHL Tumor Suppressor Function
Stebbins, C. E., Kaelin, W. G., & Pavletich, N. P. (1999) · Science · doi:10.1126/science.284.5413.455 · Cited by 860
Self-citationStabilization of wild-type p53 by hypoxia-inducible factor 1α
An, W. G., Kanekal, M., Simon, M. C., Maltepe, E., Blagosklonny, M. V., & Neckers, L. M. (1998) · Nature · doi:10.1038/32925 · Cited by 827
Regulation of the Hypoxia-inducible Transcription Factor 1α by the Ubiquitin-Proteasome Pathway
Kallio, P. J., Wilson, W. J., O'Brien, S., Makino, Y., & Poellinger, L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.10.6519 · Cited by 754
Tumour suppression by the human von Hippel-Lindau gene product
Iliopoulos, O., Kibel, A., Gray, S., & Kaelin, W. G. (1995) · Nature Medicine · doi:10.1038/nm0895-822 · Cited by 703
Self-citationBinding of the von Hippel-Lindau Tumor Suppressor Protein to Elongin B and C
Kibel, A., Iliopoulos, O., DeCaprio, J. A., & Kaelin, W. G. (1995) · Science · doi:10.1126/science.7660130 · Cited by 671 · cited 1×
“pVHL normally exists in cells as a complex with elongin B and elongin C rather than as a monome”
BackgroundSelf-citationKamura, T., Sato, S., Haque, D., Liu, L., Kaelin, W. G., Conaway, R. C., & Conaway, J. W. (1998) · Genes & Development · doi:10.1101/gad.12.24.3872 · Cited by 595 · cited 1×
“pVHL normally exists in cells as a complex with elongin B and elongin C rather than as a monome”
BackgroundSelf-citation
Cited by
Items 901–1,000 of 1,005
Rantanen, K., Pursiheimo, J., Högel, H., Miikkulainen, P., Sundström, J. T. T., & Jaakkola, P. (2013) · Journal of Cell Science · doi:10.1242/jcs.115667 · Cited by 28
Pascal, L. E., Ai, J., Rigatti, L. H., Lipton, A. K., Xiao, W., Gnarra, J. R., & Wang, Z. (2011) · Angiogenesis · doi:10.1007/s10456-011-9217-1 · Cited by 27
Hurst, J. H. (2016) · Journal of Clinical Investigation · doi:10.1172/jci90055 · Cited by 32
Wright, T. M., & Rathmell, W. K. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.073924 · Cited by 31
Woldemichael, G. M., Vasselli, J. R., Gardella, R. S., McKee, T. C., Linehan, W. M., & McMahon, J. B. (2006) · SLAS DISCOVERY · doi:10.1177/1087057106289234 · Cited by 28
“Biochemical studies have shown that under normoxic conditions, HIF-α subunits are regulated through their interaction with the von Hippel-Lindau (VHL) tumor suppressor protein complex, which marks them for rapid degradation by the ubiquitin-proteasome system.(1,2) In contrast, under hypoxic conditions, or, as in the c…”
BackgroundHIF inhibitors for ischemic retinopathies and cancers: options beyond anti-VEGF therapies
Subhani, S., Vavilala, D. T., & Mukherji, M. (2016) · Angiogenesis · doi:10.1007/s10456-016-9510-0 · Cited by 28
Von Hippel-Lindau Disease: Genetic and Clinical Observations
Iliopoulos, O. (2001) · KARGER eBooks · doi:10.1159/000061052 · Cited by 27
HIF gene expression in cancer therapy
Chan, D. A., Krieg, A. J., Turcotte, S., & Giaccia, A. J. (2007) · Methods in Enzymology · doi:10.1016/s0076-6879(07)35016-7 · Cited by 26
Regulation of the HIF switch in human endothelial and cancer cells
Slawski, J., Jaśkiewicz, M., Barton, A., Kozioł, S., Collawn, J. F., & Bartoszewski, R. (2024) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2024.151386 · Cited by 26
Liu, M., Du, K., Fu, Z.-X., Zhang, S., & Wu, X. (2014) · Medical Oncology · doi:10.1007/s12032-014-0394-9 · Cited by 26
“But HIF1-a becomes stable and translocates into nucleus and then, after combining with HIF1-b, takes part in many pathological and physiological processes as a transcription factor under hypoxia conditions [22].”
BackgroundLipid metabolic reprogramming by hypoxia-inducible factor-1 in the hypoxic tumour microenvironment
Seo, J., Yun, J.-E., Kim, S. J., & Chun, Y. (2022) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-022-02683-x · Cited by 28
Neurological applications of belzutifan in von Hippel-Lindau disease
Zhang, Y., Nguyen, C. C., Zhang, N., Fink, N. S., John, J. D., Venkatesh, O., Roe, J., Hoffman, S. C., Lesniak, M. S., Wolinsky, J., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac234 · Cited by 26
Wang, L., Jiang, Q., Chen, S., Wang, S., Lu, J., Gao, X., Zhang, D., & Jin, X. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106642 · Cited by 27
Oxygen sensor boosts growth factor signaling
Hung, M., Mills, G. B., & Yu, D. (2009) · Nature Medicine · doi:10.1038/nm0309-246 · Cited by 28
Oxygen as a regulator of cellular phenotypes in pregnancy and cancer
Lash, G. E., Postovit, L.-M. M., Matthews, N. E., Chung, E., Canning, M. T., Pross, H. F., Adams, M. A., & Graham, C. H. (2002) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y02-008 · Cited by 26
“Both MMP-2 and MMP-9 are secreted by invasive cells such as placental trophoblasts and metastatic carcinomas (Shimonovitz et al. 1994; Ohh et al. 2000; Canning et al. 2001).”
BackgroundBhatt, R. S., Zurita, A. J., O’Neill, A., Norden-Zfoni, A., Zhang, L., Wu, H. K., Wen, P. Y., George, D. J., Sukhatme, V. P., Atkins, M. B., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.186 · Cited by 28
Park, S., Kim, S.-J., Yu, D., Peña‐Llopis, S., Gao, J., Park, J. S., Tang, H., Chen, B., Kim, J., Norris, J., et al. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv692 · Cited by 26
Hypoxia-Inducible Factor-1 Alpha in the Heart: A Double Agent?
Hashmi, S., & Al‐Salam, S. (2012) · Cardiology in Review · doi:10.1097/crd.0b013e31826287f6 · Cited by 28
“This causes the von Hippel-Lindau tumor suppressor protein (pVHL) to interact with the α-subunit, targeting it for proteolysis by the ubiquitin–proteasome pathway.(8,9) Therefore, in normoxia, the HIF-α subunit has a very short half-life(10) and cells continuously synthesize and degrade HIF-α protein.”
BackgroundPan, T., Wang, Q., Zhu, L., Qi, J., You, T., & Han, Y. (2017) · Thrombosis and Haemostasis · doi:10.1160/th17-03-0155 · Cited by 26
HIF pathway mutations and erythrocytosis
McMullin, M. F. (2010) · Expert Review of Hematology · doi:10.1586/ehm.09.68 · Cited by 27
Mobility of the von Hippel–Lindau tumour suppressor protein is regulated by kinesin-2
Mans, D. A., Lolkema, M. P., van Beest, M., Daenen, L. G. M., Voest, E. E., & Giles, R. H. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2007.12.020 · Cited by 27
SENP1 promotes proliferation of clear cell renal cell carcinoma through activation of glycolysis
Dong, B., Gao, Y., Kang, X., Gao, H., Zhang, J., Guo, H., You, M. J., Xue, W., Cheng, J., & Huang, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.12606 · Cited by 27
“Hence, deSUMOylation of HIF-1α by SENP1 could prevent degradation of HIF-1α [14, 35, 36].”
BackgroundHeat-shock protein 90 inhibitors in antineoplastic therapy: is it all wrapped up?
Isaacs, J. S. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.6.569 · Cited by 26
“This has been well characterised for HIF-1, which is normally a labile protein under normoxic conditions, due to proteasomedependent degradation mediated by the tumour suppressor von Hippel Lindau (VHL), a primary ubiquitin protein ligase for HIF [54-56].”
BackgroundAdenosine Receptors in Neuroinflammation and Neurodegeneration
Salmaso, V., Menin, S., Moro, S., Spalluto, G., & Federico, S. (2025) · Cells · doi:10.3390/cells14201585 · Cited by 27
“Oxygen mediates a post-transcriptional modification on hypoxia-inducible factor-1 (HIF-1)- α and HIF-2 α , triggering them to proteasome degradation [43,44].”
von Hippel–Lindau protein promotes Skp2 destabilization on DNA damage
Roe, J., Kim, H. R., Hwang, I.-Y., Cho, E., & Youn, H.-D. (2011) · Oncogene · doi:10.1038/onc.2011.40 · Cited by 25
“Bacterially purified GST-pVHL was incubated with whole-cell lysates from HEK293T cells transiently expressing HA-HIF1a (left) or HEK293T cells transiently expressing HA-Skp2 (right), and precipitated with glutathione sepharose.”
MethodOsteoclasts adapt to physioxia perturbation through DNA demethylation
Nishikawa, K., Seno, S., Yoshihara, T., Narazaki, A., Sugiura, Y., Shimizu, R., Kikuta, J., Sakaguchi, R., Suzuki, N., Takeda, N., et al. (2021) · EMBO Reports · doi:10.15252/embr.202153035 · Cited by 25
“For metabolome analysis, metabolites were measured using an Orbitrap-type MS (Q-Exactive Focus; Thermo Fisher Scientific) connected to a high-performance IC system (ICS-5000 + , Thermo Fisher Scientific), as previously described (Semba et al , 2016; Okuno et al , 2020).”
Piwarski, S. A., & Salisbury, T. B. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115771 · Cited by 25
Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma
Joshi, S., Singh, A. R., & Durden, D. L. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2639-x · Cited by 25
Sumoylation of hypoxia inducible factor-1α and its significance in cancer
Li, J., Xu, Y., Jiao, H., Wang, W., Mei, Z., & Chen, G. (2014) · Science China Life Sciences · doi:10.1007/s11427-014-4685-3 · Cited by 29
Varicocele is associated with an increase of connective tissue of the pampiniform plexus vein wall
Iafrate, M., Antonio Galfano, A., Macchi, V., Ebugheme, E., Sarasin, G., Porzionato, A., Novara, G., De, R., Artibani, W., & Ficarra, V. (2008) · World Journal of Urology · doi:10.1007/s00345-008-0352-2 · Cited by 25
Höfer, T., Pohjanvirta, R., Spielmann, P., Viluksela, M., Buchmann, D. P., Wenger, R. H., & Gassmann, M. (2004) · Biological Chemistry · doi:10.1515/bc.2004.024 · Cited by 28
“…hypoxic conditions, this ubiquitously expressed complex binds to the hypoxia-response element (HRE) and activates genes involved in oxygen homeostasis, including vascular endothelial growth factor (VEGF) and erythropoietin (Epo) (reviewed by Hofer et al., 2002; Höpfl et al., 2004; Semenza, 2002).”
BackgroundPlasminogen kringle 5 suppresses gastric cancer via regulating HIF-1α and GRP78
Fang, S., Hong, H., Li, L., He, D., Xu, Z., Shaoyuan, Z., Han, J., Wu, Q., Dai, Z., Cai, W., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.528 · Cited by 25
Lacombe, C., & Mayeux, P. (2002) · Springer eBooks · doi:10.1007/978-3-7091-7658-0_1 · Cited by 25
Sousa, A., Dugourd, A. J. F., Memon, D., Pétursson, B., Petsalaki, E., Sáez-Rodríguez, J., & Beltrão, P. (2023) · Molecular Systems Biology · doi:10.15252/msb.202110631 · Cited by 24
“TFs are commonly dysregulated due to genomic alterations in their sequences or in upstream signalling regulatory proteins (Oliner et al. 1992; Ohh et al. 2000).”
BackgroundFunctional crosstalk between chromatin and hypoxia signalling
Collier, H., Albanese, A., Kwok, C.-S., Kou, J., & Rocha, S. (2023) · Cellular Signalling · doi:10.1016/j.cellsig.2023.110660 · Cited by 27
Targeting the molecular effects of a hypoxic tumor microenvironment
Cárdenas-Navia, L. I. (2007) · Frontiers in bioscience · doi:10.2741/2372 · Cited by 27
Lai, Y., Qiao, M., Song, M., Weintraub, S. T., & Shiio, Y. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016975 · Cited by 25
“. Anti-p160 rabbit polyclonal antibody was obtained from Drs. Tom Gonda and Rebecca Keough. Anti-VHL (Ig-32) was purchased from BD Pharmingen. Anti-VHL (FL-181) was purchased from Santa Cruz Biotechnology. Anti-FLAG M2 and anti-tubulin mouse monoclonal antibodies were purchased from Sigma. Anti-hydroxyproline antibody…”
MethodGiusti, S. A., & de Plazas, S. F. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22766 · Cited by 24
“DOI: 10.1002/jnr.22766 ' 2011 Wiley Periodicals, Inc. (Maxwell et al., 1999; Ohh et al., 2000).”
InfluentialChoi, J., Cho, H. K., Choi, Y. H., & Cheong, J. (2009) · Biochemical Journal · doi:10.1042/bj20090371 · Cited by 24
Impact of Genetics on the Diagnosis and Treatment of Renal Cancer
Singer, E. A., Bratslavsky, G., Middelton, L. A., Srinivasan, R., & Linehan, W. M. (2010) · Current Urology Reports · doi:10.1007/s11934-010-0156-y · Cited by 24
Guo, X. Q., Qi, L., Yang, J., Wang, Y., Wang, C., Li, Z. M., Li, L., Qu, Y., Wang, D., & Han, Z. M. (2016) · Cell and Tissue Research · doi:10.1007/s00441-016-2535-2 · Cited by 24
Huang, C., Chen, N., Wu, X., He, Y., Huang, C., Liu, H., Wang, W., & Wang, H. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.01.005 · Cited by 27
Fuse, S., Suzuki, K., Kuchimaru, T., Kadonosono, T., Ueda, H., Sato, S., Kizaka‐Kondoh, S., & Nakamura, H. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.115207 · Cited by 24
Pan, S., Chiang, W., & Chen, Y. (2020) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2020.06.006 · Cited by 26
Mutational status of VHL gene and its clinical importance in renal clear cell carcinoma
Alves, M. R., Carneiro, F. C., Lavorato-Rocha, A. M., da Costa, W. H., da Cunha, I. W., Zéqui, S. D. C., Guimarães, G. C., Soares, F. A., Carraro, D. M., & Rocha, R. M. (2014) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-014-1629-z · Cited by 24
Inhibition of Angiogenesis and HIF-1α Activity by Antimycin A1
Maeda, M., Hasebe, Y., Egawa, K., Shibanuma, M., & Nose, K. (2006) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.29.1344 · Cited by 26
Current management of renal cell carcinoma and targeted therapy.
Canda, A. E., & Kırkalı, Z. (2006) · Urology journal./Urology jornal. · Cited by 24
Ogura, M., Shibata, T., Yi, J., Liu, J., Qu, R., Harada, H., & Hiraoka, M. (2005) · Cancer Science · doi:10.1111/j.1349-7006.2005.00044.x · Cited by 26
Activation of HIF-1α mRNA by hypoxia and iron chelator in isolated rat carotid body
Roy, A., Volgin, D. V., Baby, S. M., Mokashi, A., Kubin, L. K., & Lahiri, S. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.03.073 · Cited by 24
Targeting HIF2α Translation with Tempol in VHL-Deficient Clear Cell Renal Cell Carcinoma
Sourbier, C., Srivastava, G. K., Ghosh, M. C., Ghosh, S., Yang, Y., Gupta, G. N., DeGraff, W., Krishna, M. C., Mitchell, J. B., Rouault, T. A., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.561 · Cited by 23
DCNL1 Functions as a Substrate Sensor and Activator of Cullin 2-RING Ligase
Heir, P., Sufan, R. I., Greer, S. N., Poon, B., Lee, J. E., & Ohh, M. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01342-12 · Cited by 24
“The following plasmids have been previously described: pcDNA3-T7-NEDD8, pcDNA3-T7-NEDD8 GG (where NEDD8 GG represents NEDD8 lacking the C-terminal glycine-glycine residues), pcDNA3-HA-CUL2, pcDNA3-HA-CUL2(K689R) (where CUL2 has the mutation K689R), pcDNA3-T7-VHL, pcDNA3-HA-HIF1 , pcDNA3HA-HIF2 , pcDNA3-GAL4-HA, pcDNA3…”
BackgroundSelf-citationHypoxia-inducible factor 1-alpha and vascular endothelial growth factor in cartilage tumors
Kouvaras, E., Christoni, Z., Siasios, I., Malizos, Κ. Ν., Koukoulis, G. Κ., & Ιωάννου, Μ. (2019) · Biotechnic & Histochemistry · doi:10.1080/10520295.2018.1556806 · Cited by 23
“In the presence of oxygen, HIF-1-alpha is degraded by the tumor suppressor, Von Hippel-Lindau (VHL), through the ubiquitinproteasomal pathway (Ohh et al. 2000).”
BackgroundChakraborty, A. A. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.03.012 · Cited by 25
Bunda, S., Qin, K., Kommaraju, K., Heir, P., & Ohh, M. (2014) · Oncogene · doi:10.1038/onc.2013.596 · Cited by 23
Self-citationvon Hippel-Lindau disease: recent advances and therapeutic perspectives
Richard, S. (2003) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.3.2.215 · Cited by 26
Metabolic sensors and their interplay with cell signalling and transcription
Krejčí, A. (2012) · Biochemical Society Transactions · doi:10.1042/bst20110767 · Cited by 23
Wang, J., & Pantopoulos, K. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2004.08.011 · Cited by 25
Shmueli, M. D., Levy-Kanfo, L., Haj, E., Schoenfeld, A. R., Gazit, E., & Segal, D. (2018) · Oncogene · doi:10.1038/s41388-018-0491-x · Cited by 23
Gilman, N. (2020) · Science & Technology Libraries · doi:10.1080/0194262x.2019.1703875 · Cited by 25
Bhattacharya, S., Shrimali, N. M., Mohammad, G., Koul, P. A., Prchal, J. T., & Guchhait, P. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103418 · Cited by 24
Molecular functions and significance of the MTA family in hormone-independent cancer
Ning, Z., Gan, J., Chen, C., Zhang, D., & Zhang, H. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9517-1 · Cited by 22
Khacho, M., Mekhail, K., Pilon‐Larose, K., Payette, J., & Lee, S. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01044-07 · Cited by 28
Okadaic acid promotes angiogenesis via activation of hypoxia-inducible factor-1
Kim, Y., Ahn, K.-H., Kim, S.-Y., & Jeong, J. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.10.034 · Cited by 22
TLX controls angiogenesis through interaction with the von Hippel-Lindau protein
Zeng, Z.-J., Johansson, E., Hayashi, A., Chavali, P. L., Akrap, N., Yoshida, T., Kohno, K., Izumi, H., & Funa, K. (2012) · Biology Open · doi:10.1242/bio.2012893 · Cited by 25
Takei, A., Ekström, M., Mammadzada, P., Aronsson, M., Yu, M., Kvanta, A., & André, H. (2017) · Scientific Reports · doi:10.1038/srep42546 · Cited by 22
Lee, S., Kwon, O. S., Lee, C., Won, M., Ban, H. S., & Ra, C. S. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.05.024 · Cited by 22
SALIDO, E. C., Timson, D. J., Betancor-Fernández, I., Palomino‐Morales, R., Anoz‐Carbonell, E., Pacheco‐García, J. L., Medina, M., & Pey, A. L. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12050747 · Cited by 25
Regulation of the transcriptional activation of the androgen receptor by the UXT-binding protein VHL
Chen, S., Chen, K., Zhang, Q., Cheng, H., & Zhou, R. (2013) · Biochemical Journal · doi:10.1042/bj20121711 · Cited by 22
Bacterially produced human HIF-1α is competent for heterodimerization and specific DNA-binding
Chachami, G., Paraskeva, E., Georgatsou, E., Bonanou, S., & Simos, G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.193 · Cited by 27
Hypoxia inducible factor 1α: A critical factor for the immune response to pathogens and Leishmania
Charpentier, T., Hammami, A., & Stäger, S. (2016) · Cellular Immunology · doi:10.1016/j.cellimm.2016.06.002 · Cited by 26
Hypoxia, HIFs, and Cardiovascular DevelopmentPreprint
Simon, M. C., Ramírez‐Bergeron, D. L., Mack, F. A., Hu, C., PAN, Y., & Mansfield, K. D. (2002) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2002.67.127 · Cited by 22
Consequences of VHL Loss on Global DNA Methylome
Robinson, C. M., Lefebvre, F., Poon, B. P., Bousard, A., Fan, X., Lathrop, M., Tost, J., Kim, W. Y., Riazalhosseini, Y., & Ohh, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-21524-5 · Cited by 21
Self-citationTing, K. K. Y. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1403915 · Cited by 21
“In the UPS model, both oxygen-dependent proline hydroxylation by PHDs and VHL-mediated ubiquitination are required (Maxwell et al., 1999; Cockman et al., 2000; Ohh et al., 2000; Bruick and McKnight, 2001; Epstein et al., 2001).”
Backgroundp62 functions as a signal hub in metal carcinogenesis
Zhang, Z., & Costa, M. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.04.014 · Cited by 21
Zhang, Y., Song, Y., Ren, S., Zhang, M., Zhang, Z., Fan, S., Liu, X., Peng, X., Qi, Q., Shen, X., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02506-4 · Cited by 21
Nakamura, H., Yasui, Y., & Ban, H. S. (2013) · Journal of Organometallic Chemistry · doi:10.1016/j.jorganchem.2013.04.007 · Cited by 21
Oxygen‐independent degradation of HIF‐α via bioengineered VHL tumour suppressor complex
Sufan, R. I., Moriyama, E. H., Mariampillai, A. L. D., Roche, O., Evans, A. J., Alajez, N. M., Vitkin, I. A., Yang, V. X. D., Liu, F., Wilson, B. C., et al. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900004 · Cited by 21
“Sample preparation and immunohistochemical staining were performed as described previously (Evans et al, 2007).”
InfluentialSelf-citationHematologic Aspects of Kidney Disease
Brugnara, C., & Eckardt, K. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6193-9.10056-9 · Cited by 26
Wu, J., Zhang, P., Zhang, G., Wang, H., Gu, W., Dai, B., Zhang, H., Shi, G., Shen, Y., Zhu, Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17894 · Cited by 21
Hypoxia reduces mature hERG channels through calpain up‐regulation
Lamothe, S. M., Song, W., Guo, J., Li, W., Yang, T., Baranchuk, A. M., Graham, C. H., & Zhang, S. (2017) · The FASEB Journal · doi:10.1096/fj.201700255r · Cited by 21
Tarade, D., Lee, J. E., & Ohh, M. (2019) · Nature Communications · doi:10.1038/s41467-019-11149-1 · Cited by 22
Self-citationNatriuretic peptide receptor a promotes gastric malignancy through angiogenesis process
Li, Z., Fan, H., Cao, J., Sun, G., Wang, S., Lv, J., Xuan, Z., Xia, Y., Wang, L., Zhang, D., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04266-7 · Cited by 21
Identification of novel VHL targets that are associated with the development of renal cell carcinoma
Abdulrahman, M., Maina, E. N., Morris, M. R., Zatyka, M., Raval, R. R., Banks, R. E., Wiesener, M. S., Richards, F. M., Johnson, C. M., Latif, F., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209932 · Cited by 21
“…have been ascribed to the VHL gene product, pVHL, undoubtedly a key function is the role of pVHL in regulating the degradation of the a subunits of the hypoxia-inducible transcription factors (HIF)-1 and-2 (Maxwell et al., 1999; Cockman et al., 2000; Kamura et al., 2000; Ohh et al., 2000).”
BackgroundCombination therapy targeting cancer metabolism
Wenger, J. B., Chun, S. Y., Dang, D. T., Luesch, H., & Dang, L. H. (2010) · Medical Hypotheses · doi:10.1016/j.mehy.2010.09.008 · Cited by 22
Von Hippel-Lindau syndrome: molecular mechanisms of the disease
Calzada, M. J. (2010) · Clinical & Translational Oncology · doi:10.1007/s12094-010-0485-9 · Cited by 23
Pantuck, A., THOMAS, G. V., Belldegrun, A. S., & Figlin, R. A. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.06.002 · Cited by 23
Knickelbein, J. E., Jacobs-El, N., Wong, W. T., Wiley, H. E., Cukras, C. A., MEYERLE, C. B., & Chew, E. Y. (2016) · Ophthalmology Retina · doi:10.1016/j.oret.2016.10.007 · Cited by 21
“Normally, pVHL functions as an E3 ligase that ubiquitinates hypoxia-inducible factor alpha (HIFa), leading to HIFa degradation.(8,9) Mutations in pVHL result in reduced degradation and increased”
Update on the Epidemiology and Biology of Renal Cortical Neoplasms
Collins, S., McKiernan, J., & Landman, J. (2006) · Journal of Endourology · doi:10.1089/end.2006.20.975 · Cited by 26
“12,13 Once bound by pVHL, HIF-1 (cid:2) is transported to the proteosome, where it is degraded, protecting the cell from carcinogenesis.”
Oxygen homeostasis and cancer: insights from a rare disease
Maxwell, P. H. (2002) · Clinical Medicine · doi:10.7861/clinmedicine.2-4-356 · Cited by 23
Rajankar, N., Kumar, A., & Gulbake, A. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107050 · Cited by 21
Okamoto, N., Tanaka, A., Jung, K., Karasawa, K., Orito, K., Matsuda, A., Amagai, Y., Oida, K., Ohmori, K., & Matsuda, H. (2011) · Cardiovascular Research · doi:10.1093/cvr/cvr203 · Cited by 20
Oxygen Measurement in Microdevices
Grist, S. M., Bennewith, K. L., & Cheung, K. C. (2022) · Annual Review of Analytical Chemistry · doi:10.1146/annurev-anchem-061020-111458 · Cited by 20
Sirtuins and Hypoxia in EMT Control
Aventaggiato, M., Barreca, F., Sansone, L., Pellegrini, L., Russo, M. A., Cordani, M., & Tafani, M. (2022) · Pharmaceuticals · doi:10.3390/ph15060737 · Cited by 20
Yuan, J., Mo, Y., Zhang, Y., Zhang, Y., & Zhang, Q. (2022) · Nanotoxicology · doi:10.1080/17435390.2022.2142169 · Cited by 21
“However, this canonical regulation of HIF-1a is impaired in hypoxic conditions, leading to its nuclear translocation and to form a functional dimer, HIF-1, with HIF-1b (Ohh et al. 2000).”
BackgroundEffects of point mutations in pVHL on the binding of HIF‐1α
Domene, C., & Illingworth, C. J. R. (2011) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.23230 · Cited by 21
Novel compound VHL heterozygosity ( VHL T124A/L188V) associated with congenital polycythaemia
Lorenzo, F., Yang, C., Lanikova, L., Butros, L. J., Zhuang, Z., & Prchal, J. T. (2013) · British Journal of Haematology · doi:10.1111/bjh.12431 · Cited by 20
Guo, W., Yang, Z., Xia, Q., Liu, J., Yu, Y., Li, J., Zuo, Z., Zhang, D., Li, X., Shi, X., et al. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0459-7 · Cited by 20
“HIF-1a protein is maintained at low levels under normoxia due to continuous degradation via the 26S proteasome pathway [8], whereas the protein levels increase rapidly in response to hypoxia and other stress conditions.”
RSUME inhibits VHL and regulates its tumor suppressor function
Gerez, J., Tedesco, L., Bonfiglio, J. J., Fuertes, M., Barontini, M., Silberstein, S., Wu, Y., Renner, U., Páez-Pereda, M., Holsboer, F., et al. (2014) · Oncogene · doi:10.1038/onc.2014.407 · Cited by 24
Steensel, M. A. M. V., van Geel, M., Badeloe, S., Poblete‐Gutiérrez, P., & Frank, J. (2009) · Experimental Dermatology · doi:10.1111/j.1600-0625.2008.00808.x · Cited by 21
Ubiquitin Ligases in Cancer: Ushers for Degradation
Newton, K., & Vucic, D. (2007) · Cancer Investigation · doi:10.1080/07357900701508041 · Cited by 21
“The von Hippel-Lindau protein (pVHL) is the substrate-binding component of a multiprotein E3 ubiquitin ligase complex (22).”
Background
Metadata
- Authors
- Ohh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T.-Y., Huang, L. E., Pavletich, N., Chau, V., & Kaelin, W. G.
- Affiliations
- Brigham and Women's Hospital (US)
- Memorial Sloan Kettering Cancer Center (US)
- Pennsylvania State University (US)
- Corresponding author
- Kaelin, William G.
- Venue
- Nature Cell Biology
- Published
- 2000-06-09
- Volume
- 2
- Issue
- 7
- Pages
- 423-427
- ISSN
- 1465-7392 (ISSN-L)
- 1476-4679
- OpenAlex
- W2147718842
- Cited by
- 1,577
- References
- 21
- Citations by year
- 2026: 23 · 2025: 36 · 2024: 46 · 2023: 36 · 2022: 49 · 2021: 56 · 2020: 59 · 2019: 45 · 2018: 40 · 2017: 50 · 2016: 52 · 2015: 45 · 2014: 62 · 2013: 66 · 2012: 70
- FWCI
- 33.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Cell Biology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Ear and Head Tumors
- Keywords
- von Hippel-Lindau protein, hypoxia-inducible factor, ubiquitination, F-box protein, protein-protein interaction, alpha-domain, von Hippel-Lindau disease, tumor suppressor, vascular tumors, E3 ubiquitin ligase
- MeSH terms
- Elongin, Cell Extracts, Deferoxamine, DNA-Binding Proteins, HeLa Cells, Humans, Ligases, Mutation, Nuclear Proteins, Oxygen, Protein Binding, Protein Processing, Post-Translational, Proteins, Transcription Factors, Transfection, Tumor Cells, Cultured, Ubiquitins, Protein Structure, Tertiary, Tumor Suppressor Proteins, Ubiquitin-Protein Ligases, Hypoxia-Inducible Factor 1, Von Hippel-Lindau Tumor Suppressor Protein, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.